The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
COMMENTARY
Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
The number of drug reps in Japan appears to be rapidly declining, according to a Jiho tally, which, combined with other industry data, signals that the total pharma sales force might have posted a decrease of more than 5,000 over…
To read the full story
COMMENTARY
- Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
February 9, 2021
- Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
- Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
December 28, 2020
- Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
October 23, 2020
- IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
September 16, 2020
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…